RSS-Feed abonnieren

DOI: 10.5935/2526-8732.20200008
Brazilian Society of Surgical Oncology (BSSO) considerations on peritoneal surface malignancies management during COVID-19 pandemic
Considerações da Sociedade Brasileira de Oncologia Cirúrgica (SBCO) sobre o manejo de malignidades da superfície peritoneal durante a pandemia de COVID-19
Financial support: none to declare.

ABSTRACT
The present proposal aims to support and help clinicians how to manage peritoneal surface malignancies during COVID-19 pandemic. It is based on the opinions of surgical oncologists of Brazilian Society of Surgical Oncology (BSSO) and not necessarily evidencebased instructions.
RESUMO
A presente proposta tem como objetivo apoiar e ajudar os médicos a gerenciar doenças malignas da superfície peritoneal durante a pandemia de COVID-19. É baseada nas opiniões de cirurgiões oncológicos da Sociedade Brasileira de Cirurgia Oncológica (SBCO) e não necessariamente em instruções baseadas em evidências.
Publikationsverlauf
Eingereicht: 21. April 2020
Angenommen: 30. April 2020
Artikel online veröffentlicht:
10. Juni 2020
© 2022. This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
Bruno José de Queiroz Sarmento, Daniel Paulino Santana, Andrea Petruzziello, Rafael Seitenfus, Cézar Augusto Vendas Galhardo, Paulo Henrique de Sousa Fernandes, Reitan Ribeiro, Heber Salvador de Castro Ribeiro, Alexandre Ferreira Oliveira. Brazilian Society of Surgical Oncology (BSSO) considerations on peritoneal surface malignancies management during COVID-19 pandemic. Brazilian Journal of Oncology 2020; 16: e-20200008.
DOI: 10.5935/2526-8732.20200008
-
REFERENCES
-
Chua TC,
Martin S,
Saxena A,
Liauw W,
Yan TD,
Zhao J.
et al
Evaluation of the cost-effectiveness of cytoreductive surgery and hyperthermic intraperitoneal
chemotherapy (peritonectomy) at the St George Hospital peritoneal surface malignancy
program. Ann Surg 2010; Feb; 251 (02) 323-329 https://doi.org/10.1097/SLA.0b013e3181c9b53c
MissingFormLabel
-
Aminian A,
Safari S,
Razeghian-Jahromi A,
Ghorbani M,
Delaney CP.
COVID-19 outbreak and surgical practice: unexpected fatality in perioperative period.
Ann Surg 2020; Mar; 26; Epub ahead of print
MissingFormLabel
-
Esquivel J,
Garcia SS,
Hicken W,
Seibel J,
Shekitka K,
Trout R.
Evaluation of a new staging classification and a Peritoneal Surface Disease Severity
Score (PSDSS) in 229 patients with mucinous appendiceal neoplasms with or without
peritoneal dissemination. J Surg Oncol 2014; Nov; 110 (06) 656-660 https://doi.org/10.1002/jso.23679
MissingFormLabel
-
Chua TC,
Moran BJ,
Sugarbaker PH,
Levine EA,
Glehen O,
Gilly FN.
et al
Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal
origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal
chemotherapy. J Clin Oncol 2012; Jul; 30 (20) 2449-2456 https://doi.org/10.1200/JCO.2011.39.7166
MissingFormLabel
-
Yan TD,
Deraco M,
Baratti D,
Kusamura S,
Elias D,
Glehen O.
et al
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant
peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009; Dec; 27
(36) 6237-6242 https://doi.org/10.1200/JCO.2009.23.9640
MissingFormLabel
-
Baratti D,
Kusamura S,
Cabras AD,
Laterza B,
Balestra MR,
Deraco M.
Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol
2010; Jan; 17 (01) 45-53 https://doi.org/10.1245/s10434-009-0756-2
MissingFormLabel
-
van Driel WJ,
Koole SN,
Sikorska K,
Schagen van Leeuwen JH,
Schreuder HWR,
Hermans RHM.
et al
Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 2018; Jan;
378 (03) 230-240 https://doi.org/10.1056/NEJMoa1708618
MissingFormLabel
-
Quenet F,
Elias D,
Roca L,
Goere D,
Li Ghout,
Pocard M.
et al
A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC)
for colorectal peritoneal carcinomatosis (PC):PRODIGE7. J Clin Oncol 2018; 36 (18
Suppl 1): LBA350 https://doi.org/10.1200/JCO.2018.36.18_suppl.LBA3503
MissingFormLabel
-
Nowacki M,
Alyami M,
Villeneuve L,
Mercier F,
Willaert W,
Ceelen W.
et al
Multicenter comprehensive methodological and technical analysis of 832 pressurized
intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients
for peritoneal carcinomatosis treatment: An international survey study. Eur J Surg
Oncol 2018; Jul; 44 (07) 991-996 https://doi.org/10.1016/j.ejso.2018.02.014
MissingFormLabel
-
Seitenfus R,
Kalil AN,
Barros ED,
Fedrizzi G.
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) through a single port: alternative
delivery for the control of peritoneal metastases. Rev Col Bras Cir 2018; 45 (04)
e1909 https://doi.org/10.1590/0100-6991e-20181909
MissingFormLabel
-
Delhorme JB,
Klipfel A,
D'Antonio F,
Greget MC,
Diemunsch P,
Rohr S.
et al
Occupational safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in
an operating room without laminar airflow. J Visc Surg 2019; Dec; 156 (06) 485-488
https://doi.org/10.1016/j.jviscsurg.2019.06.010
MissingFormLabel
-
Graversen M,
Lundell L,
Fristrup C,
Pfeiffer P,
Mortensen MB.
Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) as an outpatient procedure.
Pleura Peritoneum 2018; 3 (04) e20180128 https://doi.org/10.1515/pp-2018-0128
MissingFormLabel